Moreover, we identified elevated expression of wild-type CYSLTR2 in inflamed tumours carrying a mutation in GNAQ, GNA11 or PLCB4. As this expression originated from the melanoma cells specifically, wild-type CysLT2R could also be considered as a therapeutic target. Here, PLCB4 is linked to melanoma.